Results 261 to 270 of about 128,630 (294)

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Endocrine Reviews, 2023
Daniel J Drucker
exaly  

[Glucagon-like peptide 1 (GLP-1)].

MMW Fortschritte der Medizin, 2007
GLP-1 receptor agonists such as exenatide are a group of new therapeutic agents that mimic the gut-derived incretin hormone GLP-1. These drugs stimulate insulin secretion while suppressing glucagon secretion, inhibit gastric motility, reduce appetite and hence, food intake.
openaire   +1 more source

[Glucagon-like peptide-1(GLP-1)].

Nihon rinsho. Japanese journal of clinical medicine, 2004
Glucagon-like peptide-1(GLP-1), an intestinal hormone secreted by L cells in response to luminal nutrients(carbohydrate and fat), enhances glucose-induced insulin secretion. Impairment of glucose-induced insulin secretion in patients with type 2 diabetes can be restored to near-normal by GLP-1 administration.
openaire   +1 more source

Glucagon-like Peptide-1

2006
  +4 more sources

Glucagon-like peptide-1

2021
openaire   +1 more source

Glucagon-like peptide-1

Inpharma Weekly, 1992
openaire   +1 more source

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Lancet, The, 2002
Sten Madsbad, Jens J Holst Dmsci
exaly  

Glucagon-like peptide 1 receptor

AfCS-Nature Molecule Pages, 2005
Dieter Hoersch, Joerg Schrader, Ruediger Goeke   +2 more
openaire   +1 more source

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Lancet, The, 2006
Daniel J Drucker, Michael A Nauck
exaly  

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

Lancet, The, 2014
Bernard Zinman Cm, Ravi Retnakaran, Caroline K Kramer   +2 more
exaly